PAION AG : US filing by Cosmo could move the needle at the end of 2018
>Paion now expecting a lower net loss in 2018 - Paion reported 9M 2018 revenue of € 0.8k vs € 5.1m in 9M 17. The revenues in 9M 17 primarily resulted from the license agreement with US license partner Cosmo. The net loss in 9M 2018 stood at € 8.8m (9M 2017: € 8.5m).For the full year 2018 PAION expects revenues of € 3m. In case the filing of Remimazolam in Procedural Sedation in the US takes place in Q4 2018, it should trigger € 7.5m milestone payment, lifting 201...Paion is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company focusing on developing and commercializing drugs to be used in out-patient and hospital-based anesthesia, sedation and critical care services. Co.'s key compound is Remimazolam, an intravenous ultra short-acting and controllable anesthetic/sedative drug candidate in advanced stages of development for use in procedural sedation and general anesthesia.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.